Photo from wikipedia
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton’s tyrosine kinase, is indicated by the US FDA for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for… Click to show full abstract
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton’s tyrosine kinase, is indicated by the US FDA for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without chemotherapy. This broad approval, including treatment-na
Keywords:
ibrutinib;
lymphocytic leukemia;
small lymphocytic;
chronic lymphocytic;
leukemia small;
lymphocytic lymphoma
Journal Title: Haematologica
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haematologica
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!